TY - JOUR T1 - Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy JF - Anticancer Research JO - Anticancer Res SP - 2053 LP - 2060 DO - 10.21873/anticanres.15686 VL - 42 IS - 4 AU - MAYAKO UCHIDA AU - SAEKO MURATA AU - HANAE MORIKAWA AU - HIROKO YONEMITSU AU - SHIGERU ISHIDA AU - KIMITAKA SUETSUGU AU - TOSHIKAZU TSUJI AU - HIROYUKI WATANABE AU - TAKEHIRO KAWASHIRI AU - KOJI KATO AU - KEIKO HOSOHATA AU - TOSHIHIRO MIYAMOTO AU - NOBUAKI EGASHIRA AU - TSUTOMU NAKAMURA AU - KOICHI AKASHI AU - ICHIRO IEIRI Y1 - 2022/04/01 UR - http://ar.iiarjournals.org/content/42/4/2053.abstract N2 - Background/Aim: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin’s lymphoma patients. Patients and Methods: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data. Results: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%. Conclusion: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification. ER -